On March 14, 2023, Alligator published an interview with KOL on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer.
The discussion features Professor Jean-Luc Van Laethem, Principal Investigator of the OPTIMIZE-1 trial, and Dr. Sumeet Ambarkhane, Chief Medical Officer of Alligator Bioscience. They discuss perspectives on the current standard of care for patients with metastatic pancreatic cancer, what outcomes are associated with those therapies and the unmet medical needs.
Click here for a link to the presentation.
LATEST NEWS
Notice of extraordinary general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 24 …
Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …
Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer
Interview features OPTIMIZE-1 Principal Investigator Jean-Luc Van Laethem from Erasmus Hospital and Alligator CMO Sumeet Ambarkhane OPTIMIZE …